Archives: GVB release

LAS VEGAS, Jan. 21, 2020 — GVB Biopharma, an industrial hemp company specializing in cannabinoid-based consumer products, is showcasing its 40,000 square-foot Las Vegas product manufacturing facility. Consistent with GVB Biopharma’s principled approach to ensuring quality in its consumer products, this state-of-the-art facility carries all proper licensing and operates in full compliance with all applicable regulatory requirements.

“Between our central Oregon and Las Vegas facilities, GVB Biopharma continues to position itself as an industry-leading, vertically integrated seed-to-shelf hemp cannabinoid manufacturer,” says Drew Spiegel, Chief Operating Officer at GVB Biopharma. This strategy provides quality control in every stage of operations, from selecting hemp genetics through finished product manufacturing for wholesale and retail customers.

GVB Biopharma is currently serving many of the largest consumer-facing CBD and CBG product companies in the United States, with an expanding private label and white label business segment to meet market demand. The product line from GVB Biopharma includes a wide array of cannabinoids that undergo constant testing to ensure product quality. There are many available modes of product delivery, including: gummies, capsules, pressed pills, tinctures, chocolates, lotions, balms, salves, serums, sprays and vapes.

The company expects its Las Vegas facility to help drive local economic growth in a similar manner to its hemp processing facility in central Oregon where GVB’s operations have created over 100 jobs. With its manufacturing facility in Las Vegas, GVB aims to replicate this level of economic development in Las Vegas.

The company also plans to conduct research studies to provide a better understanding of cannabigerol and other cutting-edge cannabinoids. GVB Biopharma will also expand its reach in pharmaceutical and nutraceutical markets through partnerships and alliances with like-minded companies committed to process integrity and product quality.

GVB’s fundamental commitment to quality allows the company to respond proactively to the changing cannabinoid market and to forthcoming regulations from the FDA. In a largely unregulated industry, where such quality can be unscrupulously compromised for profit, GVB Biopharma’s approach stands out for its diligence and forward thinking.

LAS VEGAS, Dec. 9, 2019 — GVB Biopharma, a leading hemp cannabinoid producer, announced today that its research and development team has identified and isolated a previously unstudied cannabinoid called cannabicitran, or CBT. This group of scientists, comprised of alumni from the world’s leading pharmaceutical companies, will be able to study the structure, function and potential benefits of CBT in extensive detail.

What little is known about CBT is that it is found in highest concentrations in the distillates from the Type III flowers of the cannabis plant, which have high levels of cannabidiol (CBD) and low levels of tetrahydrocannabinol (THC). However, compared to most other cannabinoids, it is found in relatively low concentrations. Chemically, CBT is classified as a diether, which means that it has the same chemical relationship with CBD as CBD has with THC. Since it has the special quality of being the last cannabinoid retained on the chromatography column that chemists use to identify compounds, chemists may be able to use CBT as a marker for the end of all the known cannabinoids identified from a sample.

Precious few research studies have been published on the health effects of CBT. One study, performed over 35 years ago by longtime cannabinoid researcher Mahmoud ElSohly, was promising: CBT was found to reduce pressure within the eyes in rabbits, making CBT a potential treatment for glaucoma and other conditions.

With their new identification and isolation of CBT, the research and development team at GVB Biopharma have unearthed this unstudied cannabinoid. These pioneering scientists are poised to significantly expand the public knowledge base on cannabicitran and get a clear-eyed view of its significance.

GVB Biopharma utilizes a commitment to exacting principles to deliver rigorously tested hemp and cannabinoid products to the discerning consumer. With its state-of-the-art facilities for hemp processing in Oregon and white-label consumer product manufacturing in Las Vegas, GVB Biopharma adheres to the highest standards of product quality. From testing the genetic stability of seeds, to verifying the cannabinoid capacity of its plants, to checking the purity of the distilled oil, the integrity of the GVB Biopharma process is reflected in every product.